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SUMMARY
Growing evidence implicates the importance of glia, particularly astrocytes, in neurological and psychiatric diseases. Here, we describe a
rapid and robust method for the differentiation of highly pure populations of replicative astrocytes from human induced pluripotent
stem cells (hiPSCs), via a neural progenitor cell (NPC) intermediate. We evaluated this protocol across 42 NPC lines (derived from 30
individuals). Transcriptomic analysis demonstrated that hiPSC-astrocytes from four individuals are highly similar to primary human fetal
astrocytes and characteristic of a non-reactive state. hiPSC-astrocytes respond to inflammatory stimulants, display phagocytic capacity,
and enhance microglial phagocytosis. hiPSC-astrocytes also possess spontaneous calcium transient activity. Our protocol is a reproduc-
ible, straightforward (single medium), and rapid (<30 days) method to generate populations of hiPSC-astrocytes that can be used for
neuron-astrocyte and microglia-astrocyte co-cultures for the study of neuropsychiatric disorders.
INTRODUCTION
Astrocytes are the most abundant cell type in the CNS,
rivaling the diversity of neurons in cellular morphologies,
gene expression profiles, developmental origins, physiolog-
ical properties, functions, and responses to injury and dis-
ease (Zhang and Barres, 2010). Within the human brain,
astrocytes have a variety of essential functions including
glutamate biology, axonal guidance, trophic support, in-
flammatory response and wound healing, formation of the
blood-brain barrier, and neuronal synapse formation, and
plasticity (Barres, 2008; Eroglu and Barres, 2010; Freeman
and Rowitch, 2013). Although the full contribution of astro-
cytes to neurological disease remains unresolved, astrocyte
cell-autonomous deficits have been implicated in a variety
of neurological disorders (Seifert et al., 2006; Tong et al.,
2014).Themost significantgenetic risk factor forAlzheimer’s
disease (AD), apolipoprotein E4 (APOE4), is predominantly
synthesized and secreted by astrocytes (Xu et al., 2006).
Furthermore, astrocytes derived from human induced
pluripotent stem cell (hiPSC)- or mouse-based models of
amyotrophic lateral sclerosis (DiGiorgioetal., 2008;Marche-
tto et al., 2008; Papadeas et al., 2011), Rett syndrome (Ballas
et al., 2009), and Huntington disease (Bradford et al., 2009)
damage neurons in co-culture or after transplantation.
Evolutionarily, the astrocyte-to-neuron ratio increases
from low vertebrates to rodents and to primates (Sherwood
et al., 2006). Human cortical astrocytes are larger, structur-
ally more complex and diverse, and propagate calcium
waves 4-fold faster than their rodent counterparts (Ober-
heim et al., 2009). Transplantation of human glia into
mice enhances activity-dependent plasticity and learning
(Bi et al., 2013). Given the unique biology of human astro-
cytes, it is critical that improved human-specific cell-based
systems be established to enable the study of human astro-
cyte function in health and disease.
Because of their ability to model all of the (known and
unknown) genetic risk factors underlying neuropsychiatric
disease, hiPSCs are routinely used as a source of various
types of neurons and astrocytes for study (Mertens et al.,
2016). Current hiPSC-based methods for the differentia-
tion of astrocytes typically rely on either a neural progeni-
tor cell (NPC) (Haidet-Phillips et al., 2014; Krencik et al.,
2011; McGivern et al., 2013; Serio et al., 2013; Shaltouki
et al., 2013) or oligodendrocyte progenitor cell (Jiang
et al., 2013) intermediate.While it has beenwidely demon-
strated that hiPSCs can be differentiated to functional as-
trocytes for cell-basedmodels of neuropsychiatric disorders
in vitro (Haidet-Phillips et al., 2014; McGivern et al., 2013;
Serio et al., 2013; Shaltouki et al., 2013) or engraftment
in vivo (Chen et al., 2015; Haidet-Phillips et al., 2014; Jiang
et al., 2013; Krencik et al., 2011), existingmethods are slow
(up to 6 months) (Jiang et al., 2013; Krencik et al., 2011;
Shaltouki et al., 2013) and/or require sorting to reduce
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heterogeneity (Chaboub and Deneen, 2013; Yuan et al.,
2011). Here, we screened a number of published proto-
cols, along with commercially available media for primary
human astrocyte culture, identifying a robust and straight-
forward differentiation protocol for generating astrocytes
from hiPSCs. By co-culture with microglia, we compared
the function of primary human fetal astrocytes and
hiPSC-astrocytes in assays for neuroinflammatory res-
ponse, phagocytosis, and spontaneous calcium activity,
concluding that hiPSC-astrocytes are highly similar to their
primary counterparts. Altogether, our rapid differentiation
protocol, co-culture strategy, and scalable phenotypic as-
says will serve as a robust platform for queries of healthy
and diseased human astrocytes.
RESULTS
30-Day Exposure of hiPSC-Derived NPCs to
Commercial Astrocyte Media Is Sufficient to Robustly
Generate hiPSC-Astrocytes
We first screened 11 different media conditions on fore-
brain-patterned NPCs (Brennand et al., 2015; Brennand
and Gage, 2011) derived from hiPSCs (Table 1). The
screening conditions, based on recently published hiPSC-
astrocyte differentiation protocols (Chen et al., 2015; Hai-
det-Phillips et al., 2014; Jiang et al., 2013; Krencik et al.,
2011; McGivern et al., 2013; Serio et al., 2013; Shaltouki
et al., 2013), included different combinations of fibroblast
growth factor 2 (FGF2) (Haidet-Phillips et al., 2014), ciliary
neurotrophic factor (CNTF), (Krencik et al., 2011; Shaltouki
et al., 2013), bone morphogenetic protein 4 (BMP4) (Han
et al., 2013; Jiang et al., 2013; Shaltouki et al., 2013), fibro-
blast bovine serum (FBS) (Han et al., 2013; Shaltouki
et al., 2013), neuregulin (Pinkas-Kramarski et al., 1994;
Shaltouki et al., 2013), insulin (Heni et al., 2011), and ascor-
bic acid (AA) (Palm et al., 2015), as well as three commer-
cial astrocyte media (ScienCell, Gibco, and Lonza) for
the culture of primary human fetal astrocytes (Table 1).
Screening criteria included immunoreactivity for two
classicalmarkers of astrocyte identity, S100b and glial fibril-
lary acidic protein (GFAP) (Ludwin et al., 1976), astrocyte
morphology, survival, replicative ability, and cell line
variability (Table S1; Figure S1A). When tested on NPCs,
most conditions resulted in limited cell proliferation
and expression of neuronal markers (Table S1); however,
Table 1. Screening Conditions for Astrocyte Differentiation
ID Reference Basal Medium Supplement 1 Supplement 2 Growth Factors
1 Brennand and Gage (2011) DMEM/F12 N2, B27 GlutaMAX + sodium
bicarbonate + sodium
pyruvate
BDNF GDNF cAMP AA
2 ScienCell 1801 ND (AM) AGS 2% FBS
3 Thermo Fisher A1261301 DMEM N2 GlutaMAX + D-glucose +
sodium pyruvate
10% FBS
4 Lonza CC-3186 ND – L-glutamine EGF 3% FBS insulin + AA
5 C.M.K., unpublished data neural basal
glutamine
23 N2 FGF2 + CNTF




N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF
7 Krencik et al. (2011) DMEM/F12 N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF
8 Jiang et al. (2013) DMEM/F12 N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF BMP4
9 reduction of % FBS
from no. 10
DMEM/F12 N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF BMP4 3% FBS
10 Roybon et al. (2013) DMEM/F12 N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF BMP4 10% FBS
11 Shaltouki et al. (2013) DMEM/F12 N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF BMP4 3% FBS neuregulin
12 adding insulin + AA
to no. 9
DMEM/F12 N2, B27 GlutaMAX, NEAA, bME FGF2 + CNTF BMP4 3% FBS insulin + AA
The 11 screened conditions of astrocyte differentiation from hiPSCs, including 3 commercially available astrocyte media (nos. 2–4) and 8 conditions modi-
fied from published protocols (nos. 5–12), with a forebrain neuron differentiation protocol (no. 1). NEAA, non-essential amino acid; bME, 2-mercaptoetha-
nol; AA, ascorbic acid; ND, non-disclosure; AM, astrocyte medium; AGS, astrocyte growth supplement.
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two commercial media, ScienCell and Lonza, yielded
S100b- and GFAP-positive astrocyte-like cells (Figures S1B–
S1D). These results were confirmed across four representa-
tive NPC lines by both flow cytometry and immunocyto-
chemistry by 30 days (Figures 1A and S1E–S1G). Culture
of NPCs in both media, when combined with low initial
seeding density (nearly single cells: 15,000 cells/cm2) and
minimal serum exposure (1%–2%), resulted in astrocyte
morphologywithin 10 days (Figure S1H); star-shaped astro-
cytemorphologieswere evidentwithin 30 days (Figure S1I).
Although ScienCell and Lonza astrocyte media showed
equivalent efficiencies (Figures S1B–S1D), ScienCell me-
dium was selected owing to its lower cost and relative
simplicity.
We next tested the efficacy of this protocol across 42 NPC
lines from30 individuals (includinghealthy controls aswell
as cases with schizophrenia and frontotemporal dementia;
16 male and 14 female) generated as part of three unique
hiPSC cohorts (reprogrammed and differentiated through
different protocols in independent laboratories) (Table S2).
All 42 NPC lines ultimately yielded replicative cells with
an astrocyte-like morphology (although not necessarily on
the first attempt), with an average composition of 90%
S100b+ and 82% GFAP+ cells by flow cytometry, relative to
the appropriate secondary antibody control (Figures 1A
and 1B; hiPSCs served as a negative control, lacking S100b-
and GFAP-positive cells), and confirmed by immunocyto-
chemistry (Figures 1A, 1C, S1J, and S1K). As with primary
astrocytes (Figures 1G and S1O), there is substantial vari-
ability in mean fluorescent intensity between S100b- and
GFAP-positive hiPSC-astrocyte populations (Figure 1A).
Within 30 days, hiPSC-astrocytes were immunopositive
for the astrocyte markers ALDH1L1 (Cahoy et al., 2008)
and Vimentin (VIM) (Schnitzer et al., 1981), as well as the
glutamate transporters GLAST (EAAT1 and GLUT1) (Roth-
stein et al., 1994) (Figures 1C, S1L, and S1M). Compared
withNPCsor excitatoryneurons (hNGN2-inducedneurons)
(Brennand et al., 2015), hiPSC-astrocytes expressed GFAP
(Ludwin et al., 1976), S100b (Ludwin et al., 1976), VIM
(Schnitzer et al., 1981), AQU4 (Hubbard et al., 2015),
ACSBG1 (Chaboub and Deneen, 2013), and APOE (Boyles
et al., 1985) by qPCR (Figure 1D), although expression
levels between individual hiPSC-astrocytes and primary
astrocyte lines varied substantially. In addition,hiPSC-astro-
cytes expressed low levels of the neuronal markers TUJ1,
MAP2AB, RELN, and CACNA1C (Figure 1E).
Across a larger panel of neural lineage markers (Table S4)
in 23 hiPSC-astrocyte lines and their isogenic NPC lines,
principal component analysis (PCA) revealed that the
NPCs grouped together, while the astrocytes (both hiPSC-
derived and primary human fetal astrocytes) were more
dispersed (Figures 1F and S1N). Because it was apparent in
our hiPSC-astrocytes as well as the primary human fetal
astrocytes (obtained from different donors and brain re-
gions), this variability in lineage marker expression may
reflect inter-individual variability and/or differences in
regional patterning (Figures 1G and S1O).
hiPSC-Astrocytes and Primary Human Fetal Astrocytes
Share Similar Transcriptional Profiles
To query the extent to which global gene expression in
hiPSC-astrocytes resembles primary human fetal brain
astrocytes, we performed RNA sequencing (RNA-seq) tran-
scriptomic analyses on four control hiPSC-astrocytes and
primary human fetal astrocytes from two brain regions
(cerebral cortex and midbrain), together with isogenic
Figure 1. Rapid Differentiation of hiPSC-Derived NPCs to Astrocyte-like Identity
(A) Representative flow-cytometry analysis of S100b (top) and GFAP (bottom) for four 30-day hiPSC-astrocyte differentiations. Arrows
indicate the cells positive for each marker protein. Appropriate secondary-only control is shown in black.
(B) Graphs of flow-cytometry analysis across 35 hiPSC-astrocyte differentiations from 26 NPC lines from three independent hiPSC cohorts.
S100b (left) and GFAP (right) immunostaining is shown, with primary human fetal astrocytes (positive control) and hiPSCs (negative
control).
(C) Representative immunofluorescence images of hiPSC-astrocytes stained for astrocyte markers, glutamate transporters GLAST (green),
VIMENTIN (green), ALDH1L1 (red), and APOE (green). Scale bars, 100 mm.
(D) mRNA levels of astrocyte markers: S100b, GFAP, VIM, AQU4, ACSBG1, and APOE in hiPSC-astrocytes (n = 3 from four different lines) and
primary human fetal astrocytes (pAstrocytes; n = 3 from cerebral cortex astrocytes). Primer sequences are listed in Table S3. n, the number
of independent experiments.
(E) mRNA levels of neuronal markers: TUJ1, MAP2AB, RELN, and CACNA1C in hiPSC-astrocytes (n = 3 from four different lines) and
pAstrocytes (n = 3 from cerebral cortex astrocytes), relative to hNGN2-induced neurons (n = 3 from two lines). Primer sequences are listed
in Table S3.
(F) Principal component analysis of lineage-specific marker expression in 23 pairs of hiPSC-astrocytes and isogenic source NPCs, together
with four pAstrocyte lines isolated from fetal cerebral cortex, midbrain, cerebellum, and whole brain.
(G) Flow-cytometry analysis of S100b (top) and GFAP (bottom) for pAstrocytes from the cerebral cortex, midbrain, cerebellum, and whole
brain. Appropriate secondary-only control is shown in black. CC, cerebral cortex; Mid, midbrain; Cereb, cerebellum; Mixed, whole brain;
hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes.
Data are presented as mean ± SD using two-tailed homoscedastic Student’s t test. **p < 0.01, ***p < 0.001.
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hiPSC-derived NPCs and neurons (Figures 2 and S2),
comparing them with in vivo human and rodent astrocyte
transcriptomic datasets (Figures 2, 3, S2, and S3). hiPSC-
astrocytes showed transcriptional profiles most similar
to those of fetal brain astrocytes. Using PCA and hierar-
chical clustering, all four hiPSC-astrocytes clustered
together with the primary human fetal astrocytes and
distinct from the NPC and neuron clusters (Figures 2A,
2B, and S2A).
There were nearly 6-fold fewer differentially expressed
genes (DEGs) between hiPSC-astrocytes and primary hu-
man fetal astrocytes (900 genes) than between hiPSC-as-
trocytes and isogenic hiPSC-derived neurons (10,000
genes) or NPCs (5,500 genes) (Figures 2C and S2B).
hiPSC-astrocytes are highly similar to primary human fetal
astrocytes (r = 0.945); the majority of both expressed
genes (counts per million [CPM] > 1) and enriched genes
(CPM > 5) were shared between hiPSC-astrocytes and pri-
mary human fetal astrocytes (87.0% and 90.3%, respec-
tively) (Figure 2D). Functional enrichment analyses (using
MSigDB) demonstrated that signals regulating neuronal
maturation, such as synapse or ion channel formation,
were downregulated in hiPSC-astrocytes and primary
human fetal astrocytes, whereas signals promoting extra-
cellular cell adhesion and interaction were upregulated
(Figure 2E). When we specifically considered just the top
100 most varying genes distinguishing hiPSC-astrocytes
from hiPSC-derived NPCs and neurons, functional enrich-
ment analysis identified a group of 19 genes related to
reactivity, cytokine, interferon, T cell receptor (TCR), and
antigen-processing signaling that were enriched in astro-
cytes (G2) (Figures 3A and S2C; Table 2).
To assess the extent to which hiPSC-astrocytes are
related to human brain astrocytes in vivo, we compared
expression profiles of hiPSC-derived astrocytes, NPCs,
and neurons from four healthy controls, as well as pri-
mary human fetal astrocytes, with the Allen BrainSpan
Atlas of the Developing Human Brain (http://www.
brainspan.org) (Miller et al., 2014) using a Spearman
rank correlation analysis. Heatmaps generated through a
Wilcoxon’s rank-sum test revealed that gene expression
in hiPSC-astrocytes and primary human fetal astrocytes
was highly correlated with gene expression in human
fetal cortical brain tissue (8–16 weeks post conception)
(Figure 2F). Unsupervised hierarchical cell-type-specific
cluster analysis demonstrated that hiPSC-astrocytes
closely cluster with astrocytes purified by immunopan-
ning from human brain tissue, particularly hippocam-
pal astrocytes, rather than oligodendrocytes, endothelial
cells, myeloid cells, or neurons (Zhang et al., 2016)
(Figure 3A); pathway analysis further revealed that
many astrocyte-enriched genes were related to immune
signaling (Figure 2G).
Expression Profile of hiPSC-Astrocytes Resembles
Quiescent Astrocytes
To determine whether the gene expression pattern of our
control hiPSC-astrocytes more resembles quiescent or reac-
tive astrocytes, we compared themwith anRNA-seq dataset
of ‘‘proinflammatory’’ A1-type and ‘‘immunoregulatory’’
A2-type murine astrocytes, as well as their saline- and
sham-treated controls (Zamanian et al., 2012). (Because
these are in vivo cell types, whereby A1-type astrocytes are
induced by a bacterial lipopolysaccharide [LPS] infection
and A2-type astrocytes by middle cerebral artery occlusion
[MCAO], no comparable dataset exists for human astro-
cytes.) hiPSC-astrocyte gene expression best clusters with
the control conditions (Figures 3B and S3A), suggesting
that hiPSC-astrocytes may be closer to the quiescent state
than to reactive astrocytes.
Figure 2. Transcriptional Profile of hiPSC-Astrocytes and Primary Human Fetal Astrocytes
RNA-seq analysis of hiPSC-derived NPCs (n = 8), neurons (n = 6), and astrocytes (n = 4) together with pAstrocytes from human fetal cerebral
cortex and midbrain.
(A and B) Principal component (P.Co) analysis (A) and clustering diagram (B) of hiPSC-derived NPCs, neurons, and astrocytes, together
with pAstrocytes.
(C) Volcano plot comparison of hiPSC-astrocytes to pAstrocytes (top), as well as to hiPSC-derived NPCs (middle) and neurons (bottom).
Average log2(fold change) versus log10(FDR) is shown for all genes. Genes upregulated and downregulated by 2-fold change and FDR <
0.05 are labeled by red dots. The number of genes differentially expressed between different cell types is indicated by the red color density
and quantified in Figure S2B.
(D) Scatterplot (left) comparing gene expression in hiPSC-astrocytes and pAstrocytes. r represents the Spearman correlation coefficient.
Venn diagram (right) of overlapping gene expression (CPM > 5) between hiPSC-astrocytes and pAstrocytes.
(E) Functional pathway enrichment analysis of differentially expressed genes between hiPSC-astrocytes and pAstrocytes (left), hiPSC-
astrocytes and NPCs (middle), and pAstrocytes and NPCs (right); hiPSC-astrocytes and pAstrocytes express increased extracellular cell
communication signals, but decreased neuronal signals relative to NPCs.
(F) Heatmap produced by Wilcoxon’s rank-sum comparisons of hiPSC-derived NPCs, neurons, and astrocytes, as well as pAstrocytes, relative
to the Allen BrainSpan Atlas.
(G) Fold enrichment from functional pathway analysis of astrocyte-enriched genes, group G2 sorted from top 100 most variable genes from
Figure S3A and Table 2.
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hiPSC-Astrocytes Secrete Cytokines in Response to
Inflammatory Stimuli
A key effector of the astrocyte neuroinflammatory response
in neurodegenerative diseases is interleukin 6 (IL-6) (Zhao
and Schwartz, 1998). Consistent with effects observed
in primary human fetal astrocytes (Figure 3C), 24-hr treat-
ment with polyinosinic-polycytidylic acid (poly(I:C))
(50 ng/mL or 100 ng/mL), LPS (10 mg/mL or 50 mg/mL),
andb-amyloid 42 (Ab42) (5mMor10mM) led todose-depen-
dent increases in IL-6 secretion in control hiPSC-astrocytes
(Figure 3D), but not the source hiPSC-derived NPCs
(Figure 3C).
To more fully characterize the release of inflammatory
mediators from control hiPSC-astrocytes following 24-hr
treatment with 5 mM Ab42, a main component of the
amyloid plaques in AD, we measured proinflammatory
(IL-1b, IL-4, IL-6, IL-8, IL-10, and tumor necrosis factor a)
and anti-inflammatory cytokines (IL-1a, IL-2, IL-12, IL-
17a, interferon-g, and granulocyte macrophage colony-
stimulating factor) by Multi-Analyte ELISArray, confirming
that Ab42 treatment primarily increased IL-6 secretion (Gar-
wood et al., 2011), as well as a second proinflammatory
cytokine, IL-8 (Figures S3B and S3C). We also measured 36
cytokines, chemokines, and acute-phase proteins using
the Proteome Profiler Human Cytokine Array (Table S5) in
baseline conditions and following 24-hr treatment with
5 mM Ab42 (Figures 3D and S3C–S3E); Ab42 increased IL-6
release in both hiPSC-astrocytes and primary human fetal
astrocytes (Figure S3D). Together, our findings indicate
that hiPSC-astrocytes are capable of secreting proinflamma-
tory cytokines in response to neuroinflammatory cues.
hiPSC-Astrocytes Display Phagocytic Capacity and
Promote Phagocytic Function of Microglia
Astrocytes can phagocytose and degrade b-amyloid in AD
(Chung et al., 2013; Wyss-Coray et al., 2003). We used
flow cytometry to examine the ability of control hiPSC-as-
trocytes to phagocytose pHrodo red conjugated myelin or
zymosan bioparticles (pHrodo red dye fluoresces red in
the acidic environment of phagosomes; zymosan is an
agonist of Toll-like receptor 2 [TLR2] [Marinelli et al.,
2015; Richard et al., 2008]). hiPSC-astrocytes, primary hu-
man fetal astrocytes, and BV2 microglia showed a similar
capacity to internalize myelin purified from brain homog-
enates, while zymosan bioparticle uptake wasmuch greater
inmicroglia (consistent with higher levels of TLR2 reported
in microglia) (Jana et al., 2008) (Figures 4A, 4B, and S4A–
S4C; Movies S1–S3). The specificity of bioparticle uptake
was confirmed by treating cells with cytochalasin D, an in-
hibitor of b-actin polymerization that reduces phagocytosis
(Figures 4A and 4B).
Although microglia are the major phagocytic cells in the
brain, astrocytes mediate microglial response to inflamma-
tory stimuli (Krencik et al., 2011; Lee and Landreth,
2010; Skripuletz et al., 2013). We repeated the pHrodo
red zymosan assay using microglia-astrocyte co-cultures;
both hiPSC-astrocytes and primary human fetal astrocytes
enhanced phagocytic capacity of BV2 mouse microglial
cells (Figures 4C and S4D). We discriminated microglia
and astrocyte phagocytic activity by labeling CD11b- and
GFAP-positive cells, respectively (Figure S4E). After 3 hr of
labeling, only the CD11b+ BV2 microglial cells phagocy-
tosed the pHrodo red zymosan bioparticles (Figure S4E)
Finally, we treated BV2 microglial cells with astrocyte
conditioned medium (ACM) for 24 hr prior to analyzing
their phagocytic capacity; pretreatment of BV2 microglial
cells with ACM from either hiPSC-astrocytes or primary
human fetal astrocytes significantly increased microglial
phagocytic capacity (Figures 4D and S4F). Taken together,
these findings show that both hiPSC-astrocytes and
primary human fetal astrocytes secrete factors that in-
crease the capacity of microglia to phagocytose zymosan
bioparticles.
hiPSC-Astrocytes Display Spontaneous Calcium
Transient Activity
We next evaluated whether control hiPSC-astrocytes
exhibit spontaneous calcium transients, as has been
Figure 3. Characterization of the Neuroinflammatory Status and Reactivity of hiPSC-Astrocytes
(A) Cluster analysis of hiPSC-derived NPCs, neurons, and astrocytes, as well as pAstrocytes, combined with a human adult brain dataset
(Zhang et al., 2016). hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes; FDR, false discovery rate; CPM, counts per
million.
(B) Cluster diagram of hiPSC-astrocytes and pAstrocytes compared with the astrocyte reactivity dataset (Zamanian et al., 2012), which was
sorted by reactivity genes enriched in the A1 (LPS-treatment), A2 (MCAO ischemia), and pan-reactive phenotypes, or related controls
(saline and sham, respectively).
(C) IL-6 secretion from pAstrocytes (cerebral cortex, midbrain, cerebellum and whole brain [mixed regions]) and negative controls
(fibroblasts and NPCs), after 24-hr treatment with 50 ng/mL or 100 ng/mL poly(I:C), 10 mg/mL or 50 mg/mL LPS, or 5 mM or 10 mMAb42 and
its relative vehicle controls (saline for poly(I:C) and LPS, and Tris-HCl [pH 8] for Ab(1–42)), as measured by ELISA.
(D) IL-6 secretion following 24-hr treatment with poly(I:C), LPS, and Ab42 across hiPSC-astrocyte differentiations from nine NPC lines
from three independent hiPSC cohorts. hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes.
Data are presented as mean ± SD using one-way ANOVA with Tukey multiple comparison test. n.s., not significant; *p < 0.05, ***p < 0.001.
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described for astrocytes (Volterra et al., 2014). We used the
calcium indicator Fluo-4AM to monitor calcium signaling
under basal conditions and in response to a pulse of extra-
cellular glutamate (3 mM) (Zhang et al., 2016). A single
pulse of glutamate produced a slow calcium response in
both hiPSC-astrocytes and primary human fetal astrocytes
(Figure 5). In addition, some cells exhibited spontaneous
calcium spikes, suggesting the presence of a network of
connected astrocytes (Scemes and Giaume, 2006) (Figures
5A–5D). To quantify these responses, we measured the







Size FE p Value FDR Overlap Genes
Antigen processing and
presentation
G2 7 19 57 151.3 1.71 3 1014 8.49 3 1011 CD74; HLA-DOA; HLA-DQA1;
HLA-DQB1; HLA-DRA; HLA-DRB1;
HLA-DRB5
Cell adhesion molecules (CAMS) G2 6 19 115 64.3 3.17 3 1010 3.61 3 107 HLA-DOA; HLA-DQA1; HLA-DQB1;
HLA-DRA; HLA-DRB1; HLA-DRB5
Reactome MHC class II antigen
presentation
G2 5 19 86 71.6 6.64 3 109 6.94 3 106 CD74; HLA-DOA; HLA-DQA1;
HLA-DRB1; HLA-DRB5
Reactome translocation of ZAP70
to immunological synapse
G2 3 19 7 528 1.58 3 108 1.53 3 105 HLA-DQA1; HLA-DRB1; HLA-DRB5
Reactome phosphorylation
of CD3 and TCR z chains
G2 3 19 10 369.6 5.42 3 108 4.85 3 105 HLA-DQA1; HLA-DRB1; HLA-DRB5
Reactome PD1 signaling G2 3 19 11 336 7.45 3 108 6.22 3 105 HLA-DQA1; HLA-DRB1; HLA-DRB5
Reactome generation of
second messenger molecules
G2 3 19 18 205.3 3.67 3 107 0.000287 HLA-DQA1; HLA-DRB1; HLA-DRB5
Reactome downstream
TCR signaling
G2 3 19 27 136.9 1.31 3 106 0.000965 HLA-DQA1; HLA-DRB1; HLA-DRB5
Neuron differentiation G1 4 28 73 45.8 1.68 3 106 0.001205 CNTN4; LMX1B; OTX2; SLIT1
Generation of neurons G1 4 28 79 42.3 2.31 3 106 0.001574 CNTN4; LMX1B; OTX2; SLIT1
Axon guidance G1 3 28 22 114 2.32 3 106 0.001574 CNTN4; OTX2; SLIT1
Neurogenesis G1 4 28 89 37.6 3.73 3 106 0.002458 CNTN4; LMX1B; OTX2; SLIT1
Nervous system development G1 6 28 366 13.7 3.95 3 106 0.002538 CNTN4; LMX1B; LY6H; OTX2;
SHOX2; SLIT1
Reactome TCR signaling G2 3 19 41 90.1 4.74 3 106 0.002876 HLA-DQA1; HLA-DRB1; HLA-DRB5
Nervous system development S1 5 17 366 18.8 4.82 3 106 0.002876 CNTN4; LMX1B; LY6H; SHOX2; SLIT1
Biocarta TCRA pathway G2 2 19 5 492.8 6.23 3 106 0.003549 HLA-DRA; HLA-DRB1
Reactome co-stimulation
by the CD28 family
G2 3 19 52 71.1 9.77 3 106 0.005322 HLA-DQA1; HLA-DRB1; HLA-DRB5
Reactome interferon-g
signaling
G2 3 19 57 64.8 1.29 3 105 0.006553 HLA-DQA1; HLA-DRB1; HLA-DRB5
Biocarta IL-5 pathway G2 2 19 7 352 1.31 3 105 0.006553 HLA-DRA; HLA-DRB1
Axonogenesis G1 3 28 42 59.7 1.71 3 105 0.007939 CNTN4; OTX2; SLIT1
Biocarta asbcell pathway G2 2 19 8 308 1.74 3 105 0.007939 HLA-DRA; HLA-DRB1
Neuron differentiation S1 3 17 73 56.6 1.92 3 105 0.00858 CNTN4; LMX1B; SLIT1
MSigDB (http://software.broadinstitute.org/gsea/msigdb) is a collection of gene annotations, including gene ontology, and functional pathways. Overlap
size: the number of genes shared between a query gene set (e.g., genes in group 1, G1) and a gene set in MSigDB (e.g., antigen processing and presentation).
Group size: the number of genes in a query gene set. MSigDB size: the number of genes in MSigDB gene set. FE, fold enrichment; FDR, false discovery rate.
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frequency of spontaneous activity, the number of sponta-
neous spikes per time, and the amplitude of the calcium
spike (Figures 5E–5G). There was no statistical difference
in the frequency and number of spikes between hiPSC-as-
trocytes and primary astrocytes. Interestingly, the ampli-
tude of the spontaneous calcium spike was significantly
higher in hiPSC-astrocytes compared with primary astro-
cytes. Taken together, the excitability of hiPSC-astrocytes
was largely indistinguishable from that of primary human
astrocytes.
DISCUSSION
We screened 11 methods to differentiate hiPSC-derived
NPCs into astrocytes, identifying a medium with low
FBS (1%–2%) that produces populations of hiPSC-astro-
cytes within 30 days. Although this is a commercial me-
dium sold for the culture of primary astrocytes, it has not
previously been demonstrated to support differentiation
of hiPSC to astrocytes. Our method is fast and robust: un-
like previous reports, it does not require prolonged culture
(6months) or a serial sorting process (Krencik et al., 2011;
Shaltouki et al., 2013; Yuan et al., 2011). This protocol was
evaluated across 42 NPC lines from 30 individuals (16
males and 14 females) generated from three independent
hiPSC cohorts (Table S2). We caution that the quality of
the starting NPC population is a critical predictor of success
and note that for a few particularly intransient NPC lines,
starting from very low-passage stocks proved critical to
the ultimate successful differentiation of hiPSC-astrocytes.
By both fluorescence-activated cell sorting and qPCR,GFAP
seems to be amore variablemarker of astrocyte fate (Figures
1A and 1B) and we recommend instead using S100b when
evaluating hiPSC-astrocyte populations; moreover, more
than any single gene, using panels ofmarkers and/or global
transcriptomic analysis more fully reveals the extent of
astrocyte patterning of each line. We also suggest that
hiPSC-astrocyte response to inflammatory stimuli might
represent a simple and easy platform by which to confirm
the functionality of hiPSC-astrocytes; astrocytes undergo
stimulation-dependent cytokine secretion, while NPCs do
not secrete cytokines.
To our knowledge, our method is distinct from others
recently reported (Chen et al., 2015; Haidet-Phillips et al.,
2014; Jiang et al., 2013; Krencik et al., 2011; McGivern
et al., 2013; Serio et al., 2013; Shaltouki et al., 2013), its
major advantage being the ease by which hiPSC-astrocytes
can be concurrently differentiated from many NPCs from
multiple individuals, owing to the simplicity of the proto-
col, and furthermore that astrocytes can be expanded for
months and cryopreserved, serving as a source of cells to
support an array of experiments. Therefore, because our
protocols for NPC and astrocyte culture are robust and
Figure 4. Impact of hiPSC-Astrocytes on
the Phagocytic Capacity of BV2 Microglial
Cells
(A) Phagocytic indices of BV2 cells, hiPSC-
astrocytes, and pAstrocytes incubated with
20 mg of pHrodo-labeled myelin for 3 hr and
analyzed by flow cytometry.
(B) Amnis images representative of pHrodo
red myelin after engulfment in hiPSC-as-
trocytes, pAstrocytes, and BV2 cells.
(C) Phagocytic indices of BV2 microglia
co-cultured with hiPSC-astrocytes and
pAstrocytes that were treated with 30 mg
of pHrodo-labeled zymosan for 3 hr and
analyzed by flow cytometry, F(3, 33) =
79.33.
(D) Phagocytic indices of BV2 microglia
treated with astrocyte conditioned medium
for 20 hr and then incubated with 30 mg of
pHrodo-labeled zymosan for 3 hr for anal-
ysis by flow cytometry, F(3, 13) = 30.80.
Data are representative of three indepen-
dent experiments from 6–8 different con-
trol hiPSC-astrocytes and 2–4 different
pAstrocytes and are shown as mean ± SEM. Similar significance was obtained in two other independent experiments. hiPSC-Astros, hiPSC-
astrocytes; pAstros, primary human fetal astrocytes. Treatment with 2 mM cytochalasin D (Cyt) was used as a negative control for
phagocytosis inhibition.
Stem Cell Reports j Vol. 9 j 600–614 j August 8, 2017 609
Figure 5. Spontaneous and Glutamate-Responsive Calcium Transients in hiPSC-Astrocytes and Primary Astrocytes
(A and C) Representative Fluo-4-stained hiPSC-astrocytes and pAstrocytes. Note similarity in shape of cells.
(B and D) Plots of fluorescence (RFUs) versus time for 25 regions of interest from hiPSC-astrocytes and pAstrocytes.
(E) Average number of spontaneously active cells per field (318 mm2) for hiPSC-astrocytes (n = 22 fields from four different lines) and
pAstrocytes (n = 12 fields from three different preparations of cerebral cortex astrocytes). n, the number of fields.
(F) Average number of calcium spikes per 348-s trace for hiPSC-astrocytes (n = 22) and pAstrocytes (n = 12).
(G) Average amplitude of calcium spike in each 348-s trace for hiPSC-astrocytes (n = 22) and pAstrocytes (n = 12). Peak excludes the
amplitude of the glutamate-induced spike. Each point represents the average multiple regions of interest per 318 mm2. Line shows mean ±
SEM. hiPSC-Astros, hiPSC-astrocytes, pAstros, primary human fetal astrocytes. Using a two-tailed Student’s t test, n.s., not significant;
**p < 0.05.
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easily scaled, this methodology is both preferable for large
case-control studies from dozens of idiopathic patients and
highly amenable to automated culture and future high-
throughput drug screens using patient-derived astrocytes
(Xu et al., 2016).
We have established a platform for querying astrocyte-
specific contributions to disease predisposition in hiPSC-
based models. hiPSC-astrocytes closely resemble primary
human fetal astrocytes, purified adult brain astrocytes
(Zhang et al., 2016), and brain tissue homogenate (Miller
et al., 2014) (Figures 2 and 3A). Although the transcrip-
tional profile of our hiPSC-astrocytes most closely resem-
bles a quiescent state (Figure 3B), hiPSC-astrocytes secrete
various cytokines and chemokines in response to neuroin-
flammatory stimuli (Figures 3C and 3D). hiPSC-astrocytes
displayed phagocytic capacity (Figure 4A) and enhanced
the phagocytic function of microglia in a co-culture
assay (Figure 4C). They also showed spontaneous calcium
transient activity and responses to glutamate stimulus (Fig-
ure 5). Moreover, because nearly pure populations of excit-
atory neurons and astrocytes from the same individual,
hiPSC clone, and even NPC batch can now be compared,
our protocol may reduce experimental variation in studies
of the cell-autonomous and non-cell-autonomous factors
underlying disease predisposition.
While many studies of neurodegeneration and synaptic
dysfunction use either primary mouse or human fetal glia
for humanneuron co-culture (Johnson et al., 2007; Kiskinis
et al., 2014; Verheyen et al., 2015), these methods are
limited by species-specific differences in astrocyte
functions and limited access to human fetal samples. Our
hiPSC-astrocytes overcome these drawbacks, making
possible hiPSC-based astrocyte-neuron (Jiang et al., 2013)
and astrocyte-microglia (Muffat et al., 2016; Pandya et al.,
2017) co-culture platforms for uncovering disease-related
mechanisms in vitro, which should help to reveal how the
crosstalk between these three neural cell types contributes
to neurological and psychiatric disease.
EXPERIMENTAL PROCEDURES
Human subject work on these de-identified control hiPSCs was
approved by the Institutional Review Board at Icahn School of
Medicine atMount Sinai. Control mouse brain tissue was obtained
from the Center for Comparative Medicine and Surgery at Icahn
School of Medicine at Mount Sinai.
NPCs and Astrocyte Cell Culture
Forebrain NPCs were maintained at high density, grown on
Matrigel (BD Bioscience) in NPC medium (DMEM/F12, 13 N2,
13 B27-RA [Invitrogen], 1 mg/mL laminin [Invitrogen], and
20 ng/mL FGF2 [Invitrogen]), and split approximately 1:3 to 1:4
every week with Accutase (Millipore). NPCs could be expanded
up to 14 passages. Forebrain NPCs were differentiated to astro-
cytes by seeding dissociated single cells at 15,000 cells/cm2 den-
sity on Matrigel-coated plates in astrocyte medium (ScienCell:
1801, astrocyte medium [1801-b], 2% fetal bovine serum
[0010], astrocyte growth supplement [1852] and 10 U/mL peni-
cillin/streptomycin solution [0503]). Initial NPC quality, seeding
density, and single-cell dissociation are critical, particularly dur-
ing the first 30 days of differentiation, in order to efficiently
generate hiPSC-astrocytes. See detailed protocol for astrocyte
differentiation from hiPSC-derived NPCs in the Supplemental
Information.
Immunocytochemistry
Cultures were washed with PBS and fixed using 4% paraformal-
dehyde (no. 15714, Electron Microscopy Sciences) for 20 min,
then washed three times with PBS 13 plus 0.01% Triton X-100
prior to preincubation with blocking solution made of PBS
13 plus 0.01% Triton X-100 and 10% donkey serum (Sigma-
Aldrich), for at least 1 hr. Cultures were then incubated in pri-
mary antibody solution overnight at 4C, followed by an incuba-
tion with secondary antibodies for 1 hr at room temperature. See
Supplemental Experimental Procedures for antibody details and
confocal microscopy.
Real-Time qPCR
The total RNA was extracted from cultured cells with an RNeasy
mini kit (no. 74106, Qiagen) and reverse transcribed into cDNA
with an iScript cDNA Synthesis kit (no. 1708890, Bio-Rad). cDNA
was used as template for the qPCR using a 7900 Real-Time PCR
system (Applied Biosystems) with Power SYBR Green PCR Master
Mix. The primers used are listed in Table S3. Gene expression
was analyzed using the DDCt method. All results were normalized
to GAPDH, b-ACTIN, and TBP (TATA-box binding protein) expres-
sion, and the values of uninduced fibroblasts were set to 1. Three
replicates were used to determine the error bars. See the Supple-
mental Information for RNA expression studies for qRT-PCR and
primer sequences.
Analysis of RNA-Seq Data
Pair-ended RNA-seq data was generated using the Illumina HiSeq
2500 platform for hiPSC-astrocytes (four lines), neurons (six lines),
and NPCs (eight lines) (Table S2), as well as for two primary astro-
cyte samples. The pair-ended sequencing reads were aligned to hu-
man hg19 genome using Star Aligner (version 2.5.0b). Following
read alignment, featureCounts (Liao et al., 2014) was used to quan-
tify the gene expression at the gene level based on Ensembl gene
model GRCh37.70. Gene expression data preprocessing and
downstream analyses, including differential gene expression and
functional enrichment, are detailed in Supplemental Experimental
Procedures.
IL-6 ELISA, Multi-Analyte ELISArray, and Protein
Array
hiPSC-astrocytes and primary astrocytes were seeded in astrocyte
medium 1 day before the experiment. Cells were treated for
24 hr with 50 ng/mL or 100 ng/mL of poly(I:C) (InvivoGen,
no. tlrl-pic), 10 mg/mL or 50 mg/mL of LPS (Sigma-Aldrich, no.
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L5886), and 5 mM or 10 mM human b-amyloid (Ab42) (California-
Peptide, no. 641-15) and vehicle control solutions (saline for
poly(I:C) and LPS or Tris-HCl for Ab42). Samples were analyzed
with IL-6 ELISA assay (Affymetrix eBioscience, no. 88-7066), Hu-
man Inflammatory Cytokines Multi-Analyte ELISArray (Qiagen,
no. MEH-004A), RT2 Profiler PCR Arrays (Qiagen), and Proteome
Profiler Human Cytokine Array (R&D Systems, no. ARY005B).
For a detailed protocol see Supplemental Experimental Procedures.
Phagocytosis Assay
Phagocytic capacity of hiPSC-astrocytes, primary astrocytes, and
BV2 cells was analyzed by incubating cells with pHrodo-labeled
zymosan (Thermo Fisher, P35364) or myelin purified from mouse
brains, and then measured by flow cytometry. Detailed protocols
for co-culture experiments and astrocyte conditioned media treat-
ment are provided in the Supplemental Experimental Procedures.
Calcium Imaging
Cells were incubated with 2 mM Fluo-4AM (Molecular Probes) and
0.02% Pluronic F 127 detergent in Krebs HEPES buffer (KHB).
Time-lapse image sequences (340 magnification) were acquired
at 0.9 Hz and analyzed by FluoroSNNAP software operated by
MATLAB. For a detailed protocol see Supplemental Experimental
Procedures.
Statistical Analysis
For all experiments, data are represented as mean ± SD or SEM of
three to five biological replicates. Statistical significance was deter-
mined using a two-tailed homoscedastic Student’s t test or one-way
ANOVA and Tukey-Kramer post hoc test for differences of means
between each group of data with parametric distribution. Signifi-
cant comparisons are labeled in the figures as *p < 0.05, **p <
0.01, and ***p < 0.001.
Extended experimental procedures and any associated references
are available in the online version of this paper.
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper
is GEO: GSE97904.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and five tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
06.018.
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